One of the candidates included in the deal has already shown promise in a phase 1a advanced breast cancer study ...

Bristol Myers Squibb (BMS) has announced positive results from a phase 3b/4 study of its oral TYK2 inhibitor Sotyktu ...

Public health, access to healthcare services, and food and nutrition are some of the most important issues facing people ...

Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and adaptability critical for success. Our worldwide team of 190,000 ...

Eli Lilly has announced that it is investing $4.5bn into a new US facility for advanced manufacturing and drug development. The Lilly Medicine Foundry will give the company the ability to research new ...

Research on the state of the customer experience (CX) that the global pharmaceutical industry provides to healthcare professionals (HCPs) has been released by DT Consulting, an Indegene company. For ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD). The ...

NHS England has announced that hundreds of babies have begun to be tested for over 200 genetic conditions as part of a study led by Genomics England. The Generation Study is evaluating the potential ...

The US Food and Drug Administration (FDA) has granted rare paediatric disease (RPD) designation to Enterprise Therapeutics’ investigational cystic fibrosis therapy. Estimated to affect more than ...

During a recent media audit on sickle cell disease, an intriguing pattern emerged that the name ‘Christopher’ was the third most mentioned term. This unexpected finding resonated with me, as I share ...

AstraZeneca’s (AZ) Tagrisso (osimertinib) has been approved by the US Food and Drug Administration (FDA) to treat a new subset of lung cancer patients. The epidermal growth factor receptor ...

Astellas Pharma’s claudin 18.2-directed cytolytic antibody has been approved by the European Commission (EC) as part of a first-line combination treatment for a subset of gastric cancer patients.